Search

Displaying results 3091 - 3100 of 7603 in total
  1. Drug

    SC12267

    go.drugbank.com/drugs/DB05125
    Investigational

    SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.

  2. Drug

    Gadofosveset trisodium

    go.drugbank.com/drugs/DB06705
    Approved

    The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]

  4. Drug

    1,2-Benzodiazepine

    go.drugbank.com/drugs/DB12537
    ApprovedInvestigationalWithdrawn

    Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. … Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.

  5. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

  6. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.

  7. Drug

    L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

    go.drugbank.com/drugs/DB06124
    Experimental

    C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal

  8. Drug

    Crobenetine

    go.drugbank.com/drugs/DB21095
    Investigational

    Crobenetine is under investigation in clinical trial NCT02273466 (Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects).

  9. Drug

    Dalzanemdor

    go.drugbank.com/drugs/DB21549
    Investigational

    Dalzanemdor is under investigation in clinical trial NCT05655520 (A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease).

  10. Drug

    Tanogitran

    go.drugbank.com/drugs/DB21367
    Investigational

    Tanogitran is under investigation in clinical trial NCT02254057 (Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects).